News
News/ News/ News/ Oncology/ R&D
Tagrisso paired with Hutchmed drug clears lung cancer test
Phil Taylor
AstraZeneca, HutchMed, Non-small cell lung cancer, Oncology, Orpathys, Tagrisso, targeted oncology
0 Comment
Sosei Heptares banks $30m milestone in Neurocrine Bio alliance
Phil Taylor
Karuna Therapeutics, Neurocrine Biosciences, partnering, Psychiatry, schizophrenia, Sosei Heptares
0 Comment
Gilead snaps up MiroBio and its checkpoint agonists for $405m
Phil Taylor
AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio
0 Comment
Amgen splashes out on ChemoCentryx and its blockbuster hopeful
Phil Taylor
Amgen, ChemoCentryx, Immunology and inflammation, M&A, nephrology, Tavneos
0 Comment
Pfizer takes pipeline blow as it abandons cardiomyopathy drug
Phil Taylor
Array Biopharma, cardiomyopathy, Pfizer, rare disease
0 Comment
News/ News/ News/ Oncology/ R&D
Keytruda fluffs its lines in prostate, liver cancer trials
Phil Taylor
immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology, Prostate cancer
0 Comment
News/ News/ News/ Oncology/ R&D
Roche adds to pipeline with Poseida, Kiniksa deals
Phil Taylor
CAR-T therapies, Genentech, Kiniksa Pharmaceuticals, partnering, Poseida Therapeutics, prurigo nodularis, Roche
0 Comment
Chinese biotech Sironax raises $200m for RIPK1 pipeline
Phil Taylor
China, Eli Lilly, financing, Genfleet Therapeutics, GlaxoSmithKline, Immunology and inflammation, Rigel Pharmaceuticals, RIPK1, Sanofi, Sironax
0 Comment